Q1 2014

Source filing unavailable

Q1 2014 · —

Revenue

$5.00M

−7.1% vs Q1 2013

Net Income

$1.37M

no prior Q1 2013 on file

EPS, diluted—

Operating Income$1,032,000−46.9%

Operating Cash Flow-$842,000—

Free Cash Flowderived-$1,322,000—

Same quarter

Metric	Q1 2014	Q1 2013
Revenue	$5.00M	$5.39M
Net Income	$1.37M	—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR